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ABSTRACT
Background: Hepatitis C (HCV) is the most common indication for liver transplantation in the US.
Objective: Since steroids are the major stimulus of viral replication, we postulated that steroid-free immu-
nosuppression might be a safer approach.
Methods: From January 1995 to October 2002, we used steroid plus calcineurin inhibitor (CNI) immuno-
suppression after liver transplantation for HCV (steroid group, n=81). From October 2002 to June 2007, 
rabbit antithymocyte globulin (RATG) induction, followed by CNI and azathioprine (RATG group, n=73) 
was utilized. 
Results: There were no differences in 1- and 3-year patient/allograft survival rates. The incidence of acute 
rejection rate (19% vs. 28%), of biopsy-proven HCV recurrence (70% vs. 75%), and chronic rejection (6% 
vs. 9%) were comparable. The mean time to develop recurrent HCV was significantly longer in the RATG 
group (16.2 vs. 9.2 months, p=0.008). The incidence of severe portal fibrosis appears to be lower in RATG 
group compared to the steroid group; 14% vs. 4% (p=0.07).
Conclusions: RATG induction is safe and effective after liver transplantation for HCV, but has no impact on 
the incidence of HCV recurrence and patient/allograft survival. However, a significant delay in time to 
HCV recurrence and a trend toward less rejection and portal fibrosis was observed.
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INTRODUCTION
H
epatitis C (HCV) is the most common 
indication for liver transplantation in 
the US, accounting for 40%–45% of 
all liver transplants [1-3]. Unfortunately, dis-
ease recurrence is universal in patients who 
are viremic before transplantation and leads to 
cirrhosis in at least 25% of patients five years 
after liver transplantation. This discouraging 
outcome makes HCV an important but still 
contentious indication for retransplantation 
[1-3].
The course of recurrent HCV is variable and 
several factors, including the type of immuno-
suppression used, have been proposed to be as-
sociated with early and more severe recurrent 
HCV. Use of steroid-free immunosuppression 
following liver transplantation has gained at-
tention in recent years due to the potential 
for fewer complications such as diabetes and 
osteopenia and also for hopefully impacting 
favorably the course of recurrent HCV [4-6]. 
Antilymphocyte antibody induction is also in-
creasingly utilized because it minimizes the 
need for calcineurin inhibitors (CNI) in the  www.ijotm.com    Int J Org Transplant Med 2011; Vol. 2 (4) 
immediate post-operative phase, hence poten-
tially limiting the renal toxicity in patients 
with preexisting renal insufficiency and also 
reduces the need for high-risk steroid treat-
ment of acute rejection [6]. In this study, we 
analyzed the outcome of patients who under-
went liver transplantation for HCV comparing 
rabbit antithymocyte globulin (RATG) induc-
tion vs. steroid induction and maintenance.
MATERIAL AND METHODS
We analyzed the outcome of liver transplan-
tation for HCV in a cohort of 154 consecu-
tive patients. From January 1995 to October 
2002, we used a CNI/steroid immunosup-
pressive protocol after liver transplantation 
for HCV (steroid group, n=81). From October 
2002 to June 2007, we administered induction 
with RATG, a CNI and azathioprine (RATG 
group, n=73). The RATG group patients re-
ceived 1.5 mg/kg of rabbit thymoglobulin be-
gun during the anhepatic phase followed by a 
repeat dose on days one, two and three. Pa-
tients were given 650 mg of acetaminophen 
and 50 mg of diphenhydramine orally before 
each RATG infusion. The recipients in the 
steroid group received 250 mg of methylpred-
nisolone during the anhepatic phase and were   
tapered from 200 mg/day to 20 mg of predni-
sone by day six followed by low dose oral ste-
roids (2.5–5 mg once daily by three months).
All patients received surgical site prophylaxis 
with a first-generation cephalosporin for 24 
hours, antifungal prophylaxis with clotrima-
zole for five days, and anti-Pneumocystis pro-
phylaxis with sulfamethoxazole/trimethoprim 
indefinitely. The prophylaxis regimen was 
tailored if there was a history of allergy to 
standard protocol drugs. Antiviral prophy-
laxis consisted of oral valganciclovir for 4–6 
months, if either donor or recipient cytomega-
lovirus (CMV) serologic status was positive. 
Oral famciclovir was used if both donor and 
recipient serologies were negative. In the event 
of donor CMV positivity and recipient CMV 
negativity, the antiviral prophylaxis continued 
out to one year and CMV antigenemia assay 
was used to detect subclinical replication that 
might dictate length of prophylaxis therapy. 
Before valganciclovir become commercially 
available (June 2001), oral ganciclovir 1000 
mg PO, TID was used.
Allograft biopsy was triggered by abnormal 
liver function tests beyond expected post-op-
erative period with or without HCV viremia. 
In addition, 27 patients in RATG group un-
derwent one-year protocol biopsy. Histologi-
cal confirmation of HCV recurrence was de-
fined in liver biopsy specimens as described by 
Ishak and collegues [7]. The time to recur-
rence was defined as “early:” from day 0 to day 
100; “intermediate:” from day 101 to day 180; 
and “late:” from day 181 to day 395.
Patient and graft survival, rejection, incidence 
of infectious complications, and the incidence 
and severity of recurrent HCV were evaluated 
in both groups. The mean follow-up was 48 
(range: 17–120) months. Statistical compari-
sons of the steroid and RATG patients were 
performed using Student’s t test, χ2 test and 
Kaplan-Meier survival analysis. A p value 
<0.05 was considered statistically significant.
RESULTS
Table 1 confirms that the demographic and 
clinical characteristics of donors and recipi-
ents in both groups were comparable. Overall, 
30-day peri-operative mortality was 14/154 
(9.1%): five (6%) in RATG group and nine 
(11%) in steroid group (p=0.9). In the RATG 
group, two patients died of primary nonfunc-
tion (PNF) and three died of sepsis. In the 
steroid group, the causes of death were PNF 
in one, sepsis in four, cerebrovascular event in 
three and pulmonary embolism in one. Over-
all, infections were the most common cause 
of patients’ mortality in both groups (36% vs. 
42%). The mean follow-up of the remaining 
139 patients was 48 months. Kaplan-Meier 
survival plots of the two groups (Figure 1) 
showed no significant difference in allograft 
and patient survival between the groups.
The incidence of bacterial or fungal infectious 
complications requiring hospital management 
was not different between the two groups 
(54.8% in the RATG group vs. 39.5% in the 
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steroid group, p=0.72). The incidence of multi-
ple re-admissions for infectious complications 
was 16.1% and 17.8% in both groups, respec-
tively (p=0.85).
The ultimate incidence of biopsy-proven HCV 
hepatitis recurrence was comparable in both 
groups (70% vs. 75%, respectively). As shown 
in Figure 2, The mean±SD time to HCV re-
currence was 16.2±2.7 (95% confidence inter-
val [CI]: 10–21) months in the RATG group 
compared to 9.2±1.3 (95% CI: 6–12) months in 
the steroid group (p=0.008). Most strikingly, 
the incidence of early HCV hepatitis recur-
rence (within three months post-transplant) 
was 9.2% in the RATG group compared to 
29.6% in the steroid group (p<0.001).
The overall acute rejection rate was 28% in 
the steroid group vs. 19% in the RATG group 
(p=0.72). The incidence of chronic rejection 
(6% vs. 9%) and fibrosing cholestatic hepatitis 
(4% vs. 1%) was comparable in both groups. 
The incidence of portal fibrosis (stage 2 or 
greater) was lower in the RATG group com-
pared to the steroid group (14% vs. 4) but did 
not reach a statistical significance (p=0.07).
DISCUSSION
Chronic infection with HCV is a frequent 
cause of cirrhosis and hepatocellular carcino-
ma worldwide, and has become the most com-
mon indication for liver transplantation in the 
US, accounting for approximately 40%–45% 
of all liver transplants [1-3]. Unfortunately, 
recurrent HCV is a universal event with seri-
ous consequences for many recipients includ-
ing cirrhosis and liver failure. Recurrent HCV 
leads to cirrhosis in 10% to 25% of transplant 
recipients within 5 to 10 years [1-3].
Several donor, recipient, and viral factors cor-
relate with HCV disease severity following 
transplantation. Some studies have suggest-
ed that recipients of living donor grafts and 
those with high pre- or post-transplantation 
viral load may be more likely to develop severe 
recurrent disease [2-4]. Patients infected with 
genotype 1 HCV and those who develop CMV 
infection are also at increased risk for severe 
Table 1: Demographic and clinical characteristics of donors and recipients in both groups
RATG Group (n=73) Steroid Group (n=81) p
Age 49.6±8 51.7±6 NS*
Male gender (n, %) 47, (64.4%) 56, (69.1%) NS
MELD (calculated) 29±7 27±6 NS
HCV genotype I 76% 74% NS
Donor age 46±6 42±8 NS
Donor sex (M/F) 38/35  42/39 NS
Donor cause of death NS
Trauma 38% 45%
CVA** 45% 42%
Anoxic 12% 7%
Other 5% 6%
Donor BMI 27.6±5 25.4±7  NS
Cold ischemic time (hour) 8.1±1.8 7.9±2.1 NS
Warm ischemic time (minutes) 40±6 42±7 NS
*NS: Not significant
**CVA: Cerebrovascular accident
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disease recurrence [2]. Immunosuppressive 
agents, specifically corticosteroids and OKT3, 
have also been identified as possible risk fac-
tors for HCV recurrence [1, 2].
It is well known that liver disease caused by 
HCV infection progresses more rapidly in im-
munosuppressed than in immunocompetent 
individuals [1]. The role of specific immuno-
suppressive agents on the evolution of post-
transplantation HCV disease has been evalu-
ated to some extent, but the results have been 
inconclusive [1-3]. Whether or not the initial 
antibody induction, the type of CNI used, the 
addition of other immunosuppressive agents, 
or steroid maintenance definitely influence 
outcome remains a matter of debate. Neverthe-
less, it is well accepted that acute rejection epi-
sodes requiring the increased use of steroids 
and/or antibodies enhance the risk of HCV re-
currence through immunological mechanisms 
[1, 2]. Therefore, optimal prevention of acute 
rejection should represent a goal for reducing 
the rate of graft HCV infection. An optimal 
immunosuppression regimen should use the 
fewest agents at the lowest effective doses in 
order to reduce toxicity and cost, but still pre-
vent rejection and disease recurrence.
Corticisteroids have been the most commonly 
used immunosuprresive agent after CNI in liv-
er transplant recipients. Unfortunately, acute 
and chronic administration of corticosteroids 
is associated with numerous adverse effects 
including hypertension, hyperglycemia, de-
layed wound healing, osteoporosis, glaucoma, 
suppressed growth, hyperlipidemia, increased 
risk of gastrointestinal ulceration, risk of fun-
gal infections, and suppression of the pitu-
itary-adrenal axis  [4-6]. In terms of the im-
pact of specific immunosuppressive agents on 
long-term outcomes of patients transplanted 
for HCV, there is little doubt that the use of 
corticosteroid boluses to treat acute cellular 
rejection is harmful to HCV-infected recipi-
ents. Thus, corticosteroid-free maintenance 
immunosuppression regimens have been in-
vestigated in several relatively small series 
of HCV+ patients. Reported benefits include 
suppression of HCV RNA levels, reduced in-
cidence of advanced fibrosis, and less severe 
recurrence of hepatitis C [8-10].
The use of induction therapy in liver trans-
plantation has not been as common as in other 
solid organ transplantation. Nevertheless, 
about 25% of liver transplant recipients receive 
induction therapy [11, 12]. Antibody induction 
is viewed with caution because it is liable to 
cause severe side effects and to promote peri-
operative complications, such as infection.
Antibody-induction therapy has been limited 
to the peri-operative period as a means of re-
Figure 1: Kaplan-Meier analysis showed 
comparable allograft (A) and patient survival (B) in 
both groups. Group I is steroid group and Group II 
received RATG.
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ducing early exposure to CNI or to obviate the 
need for large doses of peri-operative cortico-
steroids. RATG, a polyclonal antilymphocyte 
antibody preparation, is the most commonly 
used induction antibody in the US. RATG 
has been used as an induction agent in liver 
transplantation to reduce or eliminate cortico-
steroids use, minimize the use of CNI, delay 
exposure to CNI in patients with pre-existing 
renal failure, and explore the possibility of 
eliminating maintenance immunosuppression 
[11-17].
The use of RATG as part of a steroid-free 
protocol gained increasing popularity when 
an early randomized controlled trial suggest-
ed a reduced incidence of recurrent HCV in 
RATG-treated patients (50%) vs. steroid bolus 
recipients (71%), although this difference was 
not statistically significant [4]. These encour-
aging findings led to widespread use of RATG 
and as of September 2007, several centers have 
reported their experience with RATG with-
out steroids vs. steroid induction for recurrent 
HCV [11-17]. The results were conflicting, 
with several centers reporting a higher inci-
dence of acute rejection in non-RATG patients 
and others stating RATG had no impact on 
graft or patient survival. 
Eason and colleagues [13] randomized 119 
patients after liver transplantation to receive 
RATG 1.5 mg/kg on day 0 and 1, vs. methyl-
prednisone 1 g followed by a steroid taper over 
three months, combined with maintenance 
treatment of tacrolimus and MMF for three 
months. Patient and graft survival and inci-
dence of acute cellular rejection (ACR) were 
similar in both groups. Patients in the corti-
costeroid group had more severe ACR, which 
required additional steroid treatment (50% of 
patients with ACR compared with 7% in the 
RATG group). Although the study was not 
designed to evaluate specifically the treatment 
of HCV recipients, analysis of this subset of pa-
tients revealed that thymoglobulin induction 
was also associated with a reduced incidence 
of recurrent HCV. Other advantages included 
less post-transplantation diabetes mellitus, 
and CMV infection, with no increased risk of 
overall infectious complications in the RATG 
group. In our study, the incidence of recurrent 
HCV was comparable in both groups. How-
ever, the patients who received RATG had a 
significant delay in time to develop recurrent 
disease (16.2 months) compared to those who 
received steroid induction and maintenance 
(9.2 months). In addition, the RATG and ste-
roid groups had comparable rejection rates 
(19% vs. 28%) but a trend toward less portal 
fibrosis (4% vs. 14%). The fact that the RATG 
delayed recurrent hepatitis C following liver 
transplant could be related to steroid avoid-
ance or RATG itself. It was recently been 
shown that RATG-mediated immunosuppres-
sion is delivered in part via immunologically 
specific actions involving the generation of 
regulatory T cells (Treg), particularly CD4+ 
CD25high Foxp3+ cells. This is mainly due to 
RATG unique ability to convert the CD4+ 
CD25– T cells into CD4+ CD25+ T cells.18 
Tregs play a central role in viral persistence 
and immunologic reaction against HCV infec-
tion [19, 20].
Tector and colleagues [16] at Indiana Univer-
sity used RATG induction combined with de-
layed low-dose CNI treatment. They demon-
strated a one-year graft and patient survival 
of 92% and 96%, respectively, combined with 
a low incidence of ACR (6%) and a reduced 
incidence of renal complications. The most 
common adverse effects were fever, rigors, and 
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Figure 2: Time (months) to development of 
recurrent hepatitis C was longer in RATG group 
(p=0.008).  www.ijotm.com    Int J Org Transplant Med 2011; Vol. 2 (4) 
tachycardia. Our study also showed compa-
rable patient and allograft survival compar-
ing RATG with steroids. Interestingly, our 
patients who received RATG developed less 
severe portal fibrosis (4% vs. 14%) compared 
to steroid group which was not statistically 
significant and may need longer follow-up.
This study has several limitations. First, it is 
a retrospective analysis with relatively small 
sample size. Second, the follow-up was longer 
in the steroid group compare to the RATG 
group. Third, protocol biopsies were not done 
routinely.
In conclusion, our study showed that RATG 
induction therapy has similar results com-
pared to steroid regimen in terms of long-term 
patient and allograft survival, recurrent hepa-
titis C, and acute rejection. However, RATG 
delayed the time to recurrence and appeared 
to lessen the rate of progression as there was a 
trend toward lower incidence of portal fibrosis 
in the patients who received antibody induc-
tion. These encouraging findings warrant fur-
ther study and approach longer follow-up.
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